Variable | Total population | Patients with MS | Patients without MS | p-value |
---|---|---|---|---|
(n = 90) | (n = 24) | (n = 66) | ||
Age (years) | 40 ± 16 | 53 ± 12 | 35 ± 15 | <0.001 |
Male n(%) | 48 (53.3%) | 10 (41.6%) | 38 (57.5%) | 0.181 |
BMI (kg/m2) | 27.7 ± 3.3 | 31.7 ± 1.2 | 26.3 ± 2.6 | <0.001 |
Dyslipidemia n (%) | 32 (35.6%) | 22 (91.6%) | 10 (15.1%) | <0.001 |
Hypertension n (%) | 41 (45.6%) | 23 (95.8%) | 18 (27.2%) | <0.001 |
Diabetes n (%) | 10 (11.1%) | 10 (41.6%) | 0 (0%) | <0.001 |
Creatinine (mg/dl) | 1.0 (0.9-1.2) | 1.1(1.0-1.2) | 1 (0.9-1.0) | 0.004 |
Nitrotyrosine (μmol/L) | 0.31 ± 0.07 | 0.42 ± 0.03 | 0.27 ± 0.02 | <0.001 |
CRP (mg/dl) | 3.7 (1.8-5.3) | 5.3 (3.2-7.2) | 2.7 (1.7-4.0) | <0.001 |
PVCs origin site | Â | Â | Â | Â |
RVOT n (%) | 68 (75.6%) | 20 (83.3%) | 48 (72.7%) | 0.791 |
LVOT n (%) | 19 (21.1%) | 3 (12.5%) | 16 (24.2) | 0.227 |
CUSPs n (%) | 3 (3.3%) | 1 (4.1%) | 2 (3.0%) | 0.610 |
Echocardiography | Â | Â | Â | Â |
LVTDd (mm) | 50.0 ± 5.5 | 50.1 ± 5.3 | 50.0 ± 5.5 | 0.933 |
LVTSd (mm) | 28.7 ± 4.6 | 30.2 ± 4.3 | 28.1 ± 4.6 | 0.058 |
LVEF (%) | 57 ± 5 | 57 ± 3 | 57 ± 5 | 0.982 |
Medication | Â | Â | Â | Â |
ACEi/ARBs n (%) | 33 (36.7%) | 21 (87.5%) | 12 (18.1%) | <0.001 |
Beta blockers n (%) | 16 (17.8%) | 13 (54.1%) | 3 (4.5%) | <0.001 |
Lipid-lowering therapy n (%) | 29 (32%) | 19 (79.1%) | 10 (15.1%) | <0.001 |
Class I AADs n (%) | 16 (17.8%) | 11 (45.8%) | 5 (7.5%) | <0.001 |
Class III AADs n (%) | 3 (3.3%) | 2 (8.3%) | 1 (1.5%) | 0.172 |
Class IV AADs n (%) | 3 (3.3%) | 2 (8.3%) | 1 (8.3%) | 0.172 |
Follow-up months n (%) | 39 (32-45) | 35 (24-45) | 40 (34-45) | 0.356 |